- Home
- SOPH
SOPH
SOPHiA GENETICS SA
as of 09-25-2026 4:00pm EST
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 462.3M | IPO Year: | 2021 |
| Target Price: | $7.50 | AVG Volume (30 days): | 624.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $3.75 - $8.98 | Next Earning Date: | 05-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 23.09% | Revenue Growth (next year): | 19.57% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered SOPH Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of SOPHiA GENETICS SA (SOPH)
Chief Executive Officer
Avg Cost/Share
$8.33
Shares
422
Total Value
$3,515.26
Owned After
670,229
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$8.33
Shares
774
Total Value
$6,447.42
Owned After
308,318
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$7.88
Shares
5,000
Total Value
$39,416.50
Owned After
208,387
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$7.63
Shares
6,168
Total Value
$47,088.98
Owned After
338,884
SEC Form 4
Executive Chairman
Avg Cost/Share
$7.66
Shares
8,500
Total Value
$65,120.20
Owned After
3,435,822
SEC Form 4
Director
Avg Cost/Share
$8.13
Shares
6,250
Total Value
$50,817.50
Owned After
96,992
SEC Form 4
Director
Avg Cost/Share
$8.68
Shares
6,250
Total Value
$54,233.13
Owned After
96,992
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$8.68
Shares
5,000
Total Value
$43,396.50
Owned After
208,387
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Muken Ross | SOPH | Chief Executive Officer | Sep 21, 2026 | Sell | $8.33 | 422 | $3,515.26 | 670,229 | |
| CARDOZA GEORGE | SOPH | Chief Financial Officer | Sep 21, 2026 | Sell | $8.33 | 774 | $6,447.42 | 308,318 | |
| Menu Philippe | SOPH | Chief Medical Officer | Sep 14, 2026 | Sell | $7.88 | 5,000 | $39,416.50 | 208,387 | |
| Xu Zhenyu | SOPH | Chief Scientific Officer | Sep 14, 2026 | Sell | $7.88 | 4,000 | $31,537.60 | 552,887 | |
| Van Well Daan | SOPH | Chief Legal Officer | Sep 11, 2026 | Sell | $7.63 | 6,168 | $47,088.98 | 338,884 | |
| Camblong Jurgi | SOPH | Executive Chairman | Sep 10, 2026 | Sell | $7.66 | 8,500 | $65,120.20 | 3,435,822 | |
| HIBBS KATHY L | SOPH | Director | Sep 8, 2026 | Sell | $8.13 | 6,250 | $50,817.50 | 96,992 | |
| Xu Zhenyu | SOPH | Chief Scientific Officer | Aug 27, 2026 | Sell | $8.91 | 10,000 | $89,096.00 | 552,887 | |
| HIBBS KATHY L | SOPH | Director | Aug 25, 2026 | Sell | $8.68 | 6,250 | $54,233.13 | 96,992 | |
| Menu Philippe | SOPH | Chief Medical Officer | Aug 25, 2026 | Sell | $8.68 | 5,000 | $43,396.50 | 208,387 |
Compare SOPH vs Leading Stocks
See how SOPH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SOPH SOPHiA GENETICS SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.